Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
Status:
Not yet recruiting
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
This clinical trial investigates the change in prostate-specific membrane antigen (PSMA)
expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer
(CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA
expression changes tumor staging after therapy initiation. Understanding these effects can
help define the best timing to perform the PSMA positron emission tomography (PET) relative
to the start of therapy.
Phase:
Phase 4
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Oregon Health and Science University Progenics Pharmaceuticals, Inc.